Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening
Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target's perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low-throughput, constrained by the need for synthesis and purification of target compounds. We report an efficient platform for 'direct-to-biology' (D2B) screening of cysteine-targeting chloroacetamide RFs, wherein synthesis is performed in 384-well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS-CoV-2 main protease (M<sup>Pro</sup>), an established drug target for the treatment of COVID-19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a 'switch' to a reversible inhibitor series. This example of ligand discovery for M<sup>Pro</sup> illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non-covalent ligands.
Authors
- Alan R. Rendina (ORCID: https://orcid.org/0009-0003-9309-9651)
- Emma E. Cawood (ORCID: https://orcid.org/0000-0002-2707-8022)
- Sam M. Rowe (ORCID: https://orcid.org/0000-0003-4902-6685)
- Mark Skehel (ORCID: https://orcid.org/0000-0002-2432-0901)
- David House (ORCID: https://orcid.org/0000-0002-9635-2451)
- George S. Biggs (ORCID: https://orcid.org/0000-0001-6526-9236)
- Ioannis G. Riziotis (ORCID: https://orcid.org/0000-0002-4035-1839)
- Jacob T. Bush (ORCID: https://orcid.org/0000-0001-7165-0092)
- Nicholas C. O. Tomkinson (ORCID: https://orcid.org/0000-0002-5509-0133)
- Emma K. Grant (ORCID: https://orcid.org/0009-0005-5229-9125)
- Jonathan Pettinger (ORCID: https://orcid.org/0000-0002-8219-8369)
- David J. Fallon (ORCID: https://orcid.org/0000-0003-4918-160X)
- Harry Wilders (ORCID: https://orcid.org/0009-0000-2524-2063)
Institutions
- University of Strathclyde (GB)
- Age UK (GB)
- The Francis Crick Institute (GB)
- South College (US)
- North Hertfordshire College (GB)
- GlaxoSmithKline (Ireland) (IE)
Publication Details
- Journal
- Angewandte Chemie International Edition
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1002/anie.202418314
- Citations
- 12
- Primary Topic
- Click Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 3.00
Funders
- Wellcome Trust
- Francis Crick Institute
- Cancer Research UK
- Medical Research Council
- Engineering and Physical Sciences Research Council